指南与共识真菌感染

欧洲指南:成人血液病患者初级抗真菌预防——欧洲白血病感染会议更新推荐摘要

European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia.
指南 / 共识 · J Antimicrob Chemother · 2018-01-01

欧洲白血病感染会议(ECIL)采用IDSA分级系统更新成人抗真菌预防指南,并将推荐扩展至急性髓系白血病(AML)和异基因造血干细胞移植(HSCT)以外的其他血液病。当侵袭性霉菌病发生率超过8%时,泊沙康唑仍为首选药物;不同风险人群和移植阶段分别给出氟康唑、雾化脂质体两性霉素B联合氟康唑、伊曲康唑、泊沙康唑和伏立康唑的推荐强度。

要点

  • 侵袭性霉菌病发生率超过8%时,泊沙康唑仍为首选药物。
  • AML和骨髓增生异常综合征(MDS)诱导缓解化疗患者,氟康唑仍可作为替代,但需整合生物标志物筛查和影像学检查。
  • 异基因HSCT植入前低危患者仍推荐氟康唑作为初级预防;植入后合并移植物抗宿主病(GvHD)且伴其他危险因素时,泊沙康唑获强烈推荐。

核心结论

  • 当侵袭性霉菌病发生率超过8%时,泊沙康唑仍为首选药物。
  • 其他患者群体是否需要初级预防尚不明确,应根据侵袭性真菌病(IFD)的估计风险来确定。

研究设计与样本

  • 欧洲白血病感染会议(ECIL)采用IDSA分级系统更新成人抗真菌预防指南,并将推荐扩展至AML和异基因HSCT受者以外的其他血液病。

主要发现

  • AML和MDS诱导缓解化疗患者,氟康唑仍可作为替代方案,前提是作为整合治疗策略的一部分,包括生物标志物筛查和影像学检查。
  • 高危侵袭性霉菌病患者可考虑雾化脂质体两性霉素B联合氟康唑,但不鼓励使用其他多烯类剂型。
  • 异基因HSCT植入前低危侵袭性霉菌病患者仍推荐氟康唑作为初级预防;高危患者中伊曲康唑、泊沙康唑和伏立康唑仅获中等推荐。
  • 异基因HSCT植入后预防侵袭性霉菌病强烈推荐泊沙康唑,但仅限于GvHD伴随其他危险因素(如严重程度、使用替代供者或对标准皮质类固醇治疗无反应)时。

关键数值与推荐

  • 侵袭性霉菌病发生率超过8%时,泊沙康唑仍为首选药物。
  • AML和MDS诱导缓解化疗患者,氟康唑仍可作为替代方案。
  • 异基因HSCT植入前低危患者仍推荐氟康唑作为初级预防。
  • 异基因HSCT植入前高危患者,伊曲康唑、泊沙康唑和伏立康唑仅获中等推荐。
  • 异基因HSCT植入后伴GvHD及其他危险因素时,强烈推荐泊沙康唑预防侵袭性霉菌病。

临床怎么用

  • 侵袭性霉菌病发生率超过8%时,选用泊沙康唑作为首选预防药物。
  • AML和MDS诱导缓解化疗患者,氟康唑可作为替代,但需联合生物标志物筛查和影像学检查。
  • 高危侵袭性霉菌病患者可考虑雾化脂质体两性霉素B联合氟康唑,不鼓励使用其他多烯类剂型。
  • 异基因HSCT植入前低危患者选用氟康唑;高危患者中伊曲康唑、泊沙康唑和伏立康唑为中等推荐。
  • 异基因HSCT植入后伴GvHD及其他危险因素时,强烈推荐泊沙康唑。

局限性

  • 其他患者群体是否需要初级预防尚不明确,应根据IFD的估计风险来确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The European Conference on Infections in Leukaemia (ECIL) updated its guidelines on antifungal prophylaxis for adults using the grading system of IDSA. The guidelines were extended to provide recommendations for other haematological diseases besides AML and recipients of an allogeneic haematopoietic stem cell transplantation (HSCT). Posaconazole remains the drug of choice when the incidence of invasive mould diseases exceeds 8%. For patients undergoing remission-induction chemotherapy for AML and myelodysplastic syndrome (MDS), fluconazole can still offer an alternative provided it forms part of an integrated care strategy that includes screening with biomarkers and imaging. Similarly, aerosolized liposomal amphotericin B combined with fluconazole can be considered for patients at high risk of invasive mould diseases but other formulations of the polyene are discouraged. Fluconazole is still recommended as primary prophylaxis for patients at low risk of invasive mould diseases during the pre-engraftment phase of allogeneic HSCT whereas only a moderate recommendation could be made for itraconazole, posaconazole and voriconazole for patients at high risk. Posaconazole is strongly recommended for preventing invasive mould disease post-engraftment but only when graft-versus-host disease (GvHD) was accompanied by other risk factors such as its severity, use of an alternative donor or when unresponsive to standard corticosteroid therapy. The need for primary prophylaxis for other patient groups was less clear and should be defined by the estimated risk of invasive fungal disease (IFD).

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Maertens JA, Girmenia C, Brüggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018. PMID: 30085172. doi:10.1093/jac/dky286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。